Results from the trial's first year were reported at the 2024 ACR meeting, and they persuaded the FDA to approve the drug for ...

SHREVEPORT, La. - Giant cell arteritis, also known as temporal arteritis, is a less common condition where people get inflammation of the arteries that go to the head and neck. Symptoms include, head ...

NORTH CHICAGO, Ill., Feb. 28, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive ...

Please provide your email address to receive an email when new articles are posted on . Nearly all rheumatologists who responded to a recent survey reported patients with giant cell arteritis are in ...

Explore causes, symptoms and diagnosis of Giant Cell Arteritis and Temporal Arteritis including headache, vision loss and jaw ...

AbbVie (NYSE:ABBV) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed Upadacitinib as a treatment for giant cell arteritis, an autoimmune ...

Please provide your email address to receive an email when new articles are posted on . Although it is known that the selective Janus kinase (JAK) inhibitor upadacitinib (Rinvoq, AbbVie) blocks the ...

NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the ...

Recent advances in the study of inflammatory vasculitides have underscored the complexity of both giant cell arteritis (GCA) and Takayasu arteritis (TAK). Research has increasingly revealed the ...

Learn about polymyalgia rheumatica, temporal arteritis, their symptoms, causes, and treatment options to manage pain, ...

The US Food and Drug Administration (FDA) has approved a new indication for upadacitinib as a treatment for giant cell arteritis (GCA) in adults. This is the first oral JAK inhibitor indicated for GCA ...